154164-30-4
154164-30-4 结构式
基本信息
1,4-二氢-6-(1H-咪唑-1-基)-7-硝基-2,3-喹喔啉二酮单盐酸盐
YM 90K
YM-90K HCL
YM90Khydrochloride
6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-
6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione
1,4-Dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedionehydrochloride
1,4-Dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride
2,3-Quinoxalinedione,1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-,monohydrochloride
2,3-Quinoxalinedione,1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-, hydrochloride (1:1)
常见问题列表
Ki: 84 nM (AMPA receptor), 2.2 μM (Kainate receptor) and 37 μM (NMDA receptor)
YM90K co-injected with AMPA or kainate into the rat striatum protect cholinergic neurons against AMPA- or kainate-induced neurotoxicity.
YM90K shows potent suppressive activity against audiogenic seizure in DBA/2 mice; ED
50
values of YM90K against tonic seizure is 2.54 mg/kg (i.p.). The duration of the anticonvulsant effects of YM90K is 30 min.
In a global ischemia model, YM90K (15 mg/kg i.p.) significantly prevents the delayed neuronal death in the hippocampal CA1 region in Mongolian gerbils when administered 1 h after 5-min ischemia. The therapeutic time window for the neuroprotective effect of YM90K (30 mg/kg i.p.) is 6 h.
In a focal ischemia model, YM90K (30 mg/kg i.v. bolus+10 mg/kg/h for 4 h) reduces the volume of ischemic damage in the cerebral cortex in F344 rats.